Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Direct and indirect MCL1 targeting for high-efficiency therapy of lung metastasis in-vivo and on-a-chip

Award Number: R01CA300732
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/26/2026
PERIOD OF PERFORMANCE END DATE: 02/28/2031

Group Awards By:

View Award Description

Direct and indirect MCL1 targeting for high-efficiency therapy of lung metastasis in-vivo and on-a-chip - ABSTRACT Lung metastasis is the primary cause of death in osteosarcoma (OSA) patients, with 5-year survival rates of approximately 20% using current treatments. Our recent findings highlight the need to target both tumor and microenvironment-derived factors, revealing that resident lung and immune cells released growth factors that activated tumor survival pathways upon metastasis, particularly prosurvival gene, MCL1. Inhibiting MCL1, especially when combined with cyclophosphamide, showed promising results in our preclinical model studies, eradicating metastatic lesions in some cases. However, several questions remain as to the specificity of MCL1 as a target and the feasibility of targeting this prosurvival pathway for osteosarcoma treatment. To this end, in Aim 1, we will deploy a novel bioengineered bone and lung model for real-time cell tracking to definitively establish the role of MCL1 in lung metastasis and validate these findings in vivo. We will then identify MCL1 inhibitors most able to eliminate metastases in our engineered model, in vivo, and test their safety in preclinical models. In Aim 2, we will identify mechanisms linking microenvironment-driven osteosarcoma signaling and MCL1 regulation in the lung. By using ex vivo and in vivo approaches, we will pinpoint critical ligand-receptor interactions and test receptor-level inhibitors, aimed at blocking the effects, to reduce metastatic osteosarcoma MCL1 protein levels. Promising inhibitors will then be evaluated for their effectiveness in combination with low- dose MCL1 inhibitors to eliminate lung metastasis and safety in preclinical models. Overall, this proposal aims to fully validate the potential of MCL1 inhibitors and explore combinatorial therapies to enhance efficacy and reduce toxicity, using innovative tumor-host interaction models, paving the way for future clinical trials.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $625,179 )
2026	2026	OREGON HEALTH & SCIENCE UNIVERSITY	3181 SW SAM JACKSON PARK RD	PORTLAND	OR	97239	MULTNOMAH	USA	Cancer Treatment Research	000	1	3/26/2026	NEW	$625,179
														Subtotal = $625,179

Grand Total All Awards = $625,179

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Direct and indirect MCL1 targeting for high-efficiency therapy of lung metastasis in-vivo and on-a-chip

Award Number: R01CA300732

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/26/2026

PERIOD OF PERFORMANCE END DATE: 02/28/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer